Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016

This report is available at upto 25% Discount. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Global Markets Direct’s, ‘Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sorrento Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sorrento Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the pipeline therapeutic landscape of Sorrento Therapeutics, Inc.
  
• The report provides overview of Sorrento Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report assesses Sorrento Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report features Sorrento Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

• Evaluate Sorrento Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
  
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand important and diverse types of therapeutics under development for Sorrento Therapeutics, Inc.
  
• Identify potential new clients or partners in the target demographic
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Sorrento Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at upto 25% Discount. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Sorrento Therapeutics, Inc. Snapshot 7
Sorrento Therapeutics, Inc. Overview 7
Key Information 7
Key Facts 7
Sorrento Therapeutics, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Sorrento Therapeutics, Inc. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Sorrento Therapeutics, Inc. - Pipeline Products Glance 16
Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Sorrento Therapeutics, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 20
Sorrento Therapeutics, Inc. - Drug Profiles 21
Cellular Immunotherapy to Target CEA for Oncology 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Cellular Immunotherapy to Target PD-L1 for Oncology 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Cellular Immunotherapy to Target PSMA for Prostate Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BA-0702 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CBA-0710 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Cellular Immunotherapy to Target c-KIT for Solid Tumors 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Cellular Immunotherapy to Target CD123 for Acute Myeloid Leukemia 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cellular Immunotherapy to Target GD3 for Solid Tumors 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cellular Immunotherapy to Target HER-2 for Glioblastoma 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cellular Immunotherapy to Target HER2 for Oncology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cellular Immunotherapy to Target IL13R Alpha2 for Glioblastoma Multiforme 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cellular Immunotherapy to Target MUC-16 for Ovarian Cancer 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cellular Immunotherapy to Target ROR1 for Solid Tumor 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody to Inhibit CD47 for Oncology 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody to Inhibit Ghrelin for Obesity 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rituximab biosimilar 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
STI-600 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
STIA-0168 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
STIA-1011 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
STIA-1012 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
STIA-1014 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
STIA-1015 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
STIA-1110 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
STIB-0201 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
STIC-0205 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
STID-0602 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
BC-001 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
clostridium difficile vaccine 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies for Clostridium difficile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibodies for Hepatitis C 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
STI-001 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Sorrento Therapeutics, Inc. - Pipeline Analysis 57
Sorrento Therapeutics, Inc. - Pipeline Products by Target 57
Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration 59
Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type 60
Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action 61
Sorrento Therapeutics, Inc. - Recent Pipeline Updates 63
Sorrento Therapeutics, Inc. - Dormant Projects 64
Sorrento Therapeutics, Inc. - Discontinued Pipeline Products 66
Discontinued Pipeline Product Profiles 66
paclitaxel 66
Sorrento Therapeutics, Inc. - Locations And Subsidiaries 67
Head Office 67
Other Locations & Subsidiaries 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Sorrento Therapeutics, Inc., Key Information 7
Sorrento Therapeutics, Inc., Key Facts 7
Sorrento Therapeutics, Inc. - Pipeline by Indication, 2016 9
Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016 12
Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 13
Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016 14
Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15
Sorrento Therapeutics, Inc. - Phase II, 2016 16
Sorrento Therapeutics, Inc. - Phase I, 2016 17
Sorrento Therapeutics, Inc. - Preclinical, 2016 18
Sorrento Therapeutics, Inc. - Discovery, 2016 20
Sorrento Therapeutics, Inc. - Pipeline by Target, 2016 57
Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2016 59
Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2016 60
Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 61
Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2016 63
Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2016 64
Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2016 66
Sorrento Therapeutics, Inc., Subsidiaries 67

List of Figures

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 9
Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016 12
Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 13
Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016 14
Sorrento Therapeutics, Inc. - Pipeline by Top 10 Target, 2016 57
Sorrento Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2016 60
Sorrento Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 61